CN107494817A - 一种降糖降脂茶 - Google Patents
一种降糖降脂茶 Download PDFInfo
- Publication number
- CN107494817A CN107494817A CN201710739433.2A CN201710739433A CN107494817A CN 107494817 A CN107494817 A CN 107494817A CN 201710739433 A CN201710739433 A CN 201710739433A CN 107494817 A CN107494817 A CN 107494817A
- Authority
- CN
- China
- Prior art keywords
- leaf
- tea
- parts
- pot
- mulberry leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002218 hypoglycaemic effect Effects 0.000 title claims abstract description 50
- 241001122767 Theaceae Species 0.000 title claims 16
- 240000000249 Morus alba Species 0.000 claims abstract description 79
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 78
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 64
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 63
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 63
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 63
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 61
- 239000011435 rock Substances 0.000 claims abstract description 35
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 235000013616 tea Nutrition 0.000 claims description 135
- 108090000790 Enzymes Proteins 0.000 claims description 35
- 102000004190 Enzymes Human genes 0.000 claims description 35
- 229940088598 enzyme Drugs 0.000 claims description 35
- 239000007788 liquid Substances 0.000 claims description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 29
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 19
- 241000196324 Embryophyta Species 0.000 claims description 18
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 16
- 108010059892 Cellulase Proteins 0.000 claims description 10
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims description 10
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 10
- 229940106157 cellulase Drugs 0.000 claims description 10
- 244000025254 Cannabis sativa Species 0.000 claims description 9
- 108010001682 Dextranase Proteins 0.000 claims description 9
- 238000000137 annealing Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 8
- 239000003337 fertilizer Substances 0.000 claims description 8
- 238000007654 immersion Methods 0.000 claims description 8
- 229910052742 iron Inorganic materials 0.000 claims description 8
- 230000002015 leaf growth Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 239000002918 waste heat Substances 0.000 claims description 8
- 238000005516 engineering process Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 3
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 3
- 244000082204 Phyllostachys viridis Species 0.000 claims description 3
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 3
- 239000011425 bamboo Substances 0.000 claims description 3
- 235000015091 medicinal tea Nutrition 0.000 claims description 2
- 238000005096 rolling process Methods 0.000 claims description 2
- 241000218628 Ginkgo Species 0.000 claims 7
- 244000269722 Thea sinensis Species 0.000 abstract description 120
- 210000004369 blood Anatomy 0.000 abstract description 67
- 239000008280 blood Substances 0.000 abstract description 67
- 244000194101 Ginkgo biloba Species 0.000 abstract description 57
- 230000036541 health Effects 0.000 abstract description 16
- 238000000034 method Methods 0.000 abstract description 16
- 150000002632 lipids Chemical class 0.000 abstract description 6
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 41
- 239000003814 drug Substances 0.000 description 39
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 25
- 239000000203 mixture Substances 0.000 description 21
- 239000000463 material Substances 0.000 description 17
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 229940079593 drug Drugs 0.000 description 14
- 238000000227 grinding Methods 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 239000000284 extract Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 10
- 230000008569 process Effects 0.000 description 9
- 206010020772 Hypertension Diseases 0.000 description 8
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 8
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 8
- 235000009811 Momordica charantia Nutrition 0.000 description 7
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 7
- 240000001740 Momordica dioica Species 0.000 description 7
- 235000018365 Momordica dioica Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000000887 face Anatomy 0.000 description 7
- 150000008442 polyphenolic compounds Chemical class 0.000 description 7
- 235000013824 polyphenols Nutrition 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 208000001953 Hypotension Diseases 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 206010053615 Thermal burn Diseases 0.000 description 6
- 229930013930 alkaloid Natural products 0.000 description 6
- 239000003674 animal food additive Substances 0.000 description 6
- 208000029078 coronary artery disease Diseases 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 230000002526 effect on cardiovascular system Effects 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 208000021822 hypotensive Diseases 0.000 description 6
- 230000001077 hypotensive effect Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 230000003914 insulin secretion Effects 0.000 description 6
- -1 oxygen radicals Chemical class 0.000 description 6
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 6
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 150000003797 alkaloid derivatives Chemical class 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 235000009569 green tea Nutrition 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 235000015468 Lycium chinense Nutrition 0.000 description 4
- 244000241872 Lycium chinense Species 0.000 description 4
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 150000002213 flavones Chemical class 0.000 description 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002075 main ingredient Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 3
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 3
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 3
- 235000009685 Crataegus X maligna Nutrition 0.000 description 3
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 3
- 235000009486 Crataegus bullatus Nutrition 0.000 description 3
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 3
- 235000009682 Crataegus limnophila Nutrition 0.000 description 3
- 240000000171 Crataegus monogyna Species 0.000 description 3
- 235000004423 Crataegus monogyna Nutrition 0.000 description 3
- 235000002313 Crataegus paludosa Nutrition 0.000 description 3
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 3
- YXVXMURDCBMPRH-UHFFFAOYSA-N Lirinidine Natural products C1C2=CC=CC=C2C2=C(O)C(OC)=CC3=C2C1N(C)CC3 YXVXMURDCBMPRH-UHFFFAOYSA-N 0.000 description 3
- ORJVQPIHKOARKV-UHFFFAOYSA-N Nuciferine Natural products C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2C1N(C)CC3 ORJVQPIHKOARKV-UHFFFAOYSA-N 0.000 description 3
- 108010003541 Platelet Activating Factor Proteins 0.000 description 3
- 244000046146 Pueraria lobata Species 0.000 description 3
- 235000010575 Pueraria lobata Nutrition 0.000 description 3
- 235000006468 Thea sinensis Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 235000020279 black tea Nutrition 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229940046011 buccal tablet Drugs 0.000 description 3
- 239000006189 buccal tablet Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 229930184727 ginkgolide Natural products 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- ORJVQPIHKOARKV-OAHLLOKOSA-N nuciferine Chemical compound C1C2=CC=CC=C2C2=C(OC)C(OC)=CC3=C2[C@@H]1N(C)CC3 ORJVQPIHKOARKV-OAHLLOKOSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 241000522254 Cassia Species 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 229920000832 Cutin Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 229940100389 Sulfonylurea Drugs 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 2
- 239000001202 beta-cyclodextrine Substances 0.000 description 2
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 2
- 150000002216 flavonol derivatives Chemical class 0.000 description 2
- 235000011957 flavonols Nutrition 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241001552669 Adonis annua Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 241000304531 Allium macrostemon Species 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000027796 Blood pressure disease Diseases 0.000 description 1
- 208000007333 Brain Concussion Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 241000950640 Calcarius Species 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 208000009447 Cardiac Edema Diseases 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000893536 Epimedium Species 0.000 description 1
- 241000208688 Eucommia Species 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 244000111489 Gardenia augusta Species 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 241000190019 Guaiacum Species 0.000 description 1
- 235000004440 Guaiacum sanctum Nutrition 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 241000234435 Lilium Species 0.000 description 1
- 208000000501 Lipidoses Diseases 0.000 description 1
- 206010024585 Lipidosis Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241001347978 Major minor Species 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000002948 Ophiopogon intermedius Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 235000008737 Polygonatum biflorum Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 244000197580 Poria cocos Species 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 208000008348 Post-Concussion Syndrome Diseases 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 240000006079 Schisandra chinensis Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 244000185386 Thladiantha grosvenorii Species 0.000 description 1
- 235000011171 Thladiantha grosvenorii Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- UNWAHVGSROASNT-HXNJGWPRSA-N amarolide Chemical compound C[C@H]1C(=O)[C@@H](O)[C@@H]2[C@@]3(C)C(=O)[C@@H](O)C[C@@H](C)[C@@H]3C[C@@H]3[C@@]2(C)[C@H]1CC(=O)O3 UNWAHVGSROASNT-HXNJGWPRSA-N 0.000 description 1
- UNWAHVGSROASNT-UHFFFAOYSA-N amarolide Natural products CC1C(=O)C(O)C2C3(C)C(=O)C(O)CC(C)C3CC3C2(C)C1CC(=O)O3 UNWAHVGSROASNT-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- LGBHQFWRSMFRJF-UHFFFAOYSA-N butanedioic acid;oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)CCC(O)=O LGBHQFWRSMFRJF-UHFFFAOYSA-N 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 108010089934 carbohydrase Proteins 0.000 description 1
- 125000004403 catechin group Chemical group 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 235000000125 common agrimony Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- ZEACOKJOQLAYTD-UHFFFAOYSA-N flavan-3,3',4,4',5,5',7-heptol Chemical class OC1C(O)C2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 ZEACOKJOQLAYTD-UHFFFAOYSA-N 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 239000007887 hard shell capsule Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 229940126904 hypoglycaemic agent Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000037111 immune power Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 239000009427 jiangzhi Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 238000009366 sericulture Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- HSTCACQRSLZQHZ-UHFFFAOYSA-N shinjulactone H Natural products CC1CC(O)C(=O)C2(C)C1CC3OC(=O)CC4C(C)C(O)C(=O)C2C34C HSTCACQRSLZQHZ-UHFFFAOYSA-N 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000018726 traumatic encephalopathy Diseases 0.000 description 1
- 210000005239 tubule Anatomy 0.000 description 1
- 210000004026 tunica intima Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008802 xuezhikang Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical group CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种降糖降脂茶,其包含了以下重量份数的原料:荷叶30‑80份、桑叶30‑80份、银杏叶20‑60份、岩茶40‑80份。本发明采用荷叶、桑叶、银杏叶、岩茶为原料,经过酶解和发酵等工艺制得,它除了具有保健茶的功能外,还具有降血糖、降血脂等优良特性,特别适用于高血脂、高血糖人群。
Description
技术领域
本发明涉及保健茶及其制备方法领域,具体是一种降糖降脂茶及其制备方法。
背景技术
糖尿病是一种由于胰岛素分泌缺陷或胰岛素作用障碍所致的以高血糖为特征的代谢性疾病。持续高血糖与长期代谢紊乱等可导致全身组织器官,特别是眼、肾、心血管及神经系统的损害及其功能障碍和衰竭。严重者可引起失水,电解质紊乱和酸碱平衡失调等急性并发症酮症酸中毒和高渗昏迷。糖尿病是当今危害人类健康的重要疾病,目前全世界约有5%-7%的人受糖尿病困扰,被认为是继心脑血管疾病、恶性肿瘤之后,导致人类伤残、死亡的第三大杀手。
糖尿病常规治疗方法是吃降糖药物及补充胰岛素,糖尿病分为Ⅰ型和Ⅱ型,Ⅰ型糖尿病是一种自身免疫疾病,1 型糖尿病患者需终生胰岛素替代治疗。Ⅱ型糖尿病占众多糖尿病患者总数的95%左右。Ⅱ型糖尿病的原因是胰岛细胞代谢发生障碍,胰岛素分泌不足,或者产生胰岛素抵抗,是以胰岛素抵抗为主伴胰岛素分泌相对不足,或者以胰岛素分泌相对不足为主伴胰岛素抵抗导致的代谢性疾病。Ⅱ型糖尿病患者经过较大剂量多种口服药物联合治疗后HbA1c 仍大于7.0%时,就可以考虑启动胰岛素治疗。
目前临床应用的几种药物均不能够治愈糖尿病,主要是通过不同的作用机制,降低患者的血糖水平。糖尿病患者必须终生服药,药物本身对人体的毒副作用同样威胁着糖尿病人的健康。在中国,目前使用药物能够控制血糖达到正常标准的,还不到糖尿病患者总数的20%(邹大进,Ⅱ型糖尿病的祸首---胰岛素抵抗,大众医学,2002,(6):17),因此,除了筛选更加安全有效的新型药物之外,寻找其它的辅助治疗手段有效控制血糖水平,对于提高糖尿病人的健康水平同样是十分重要的。
高血脂是指血中胆固醇(TC)和/或甘油三酯(TG)过高或高密度脂蛋白胆固醇(HDL-C)过低,高脂血症的临床表现主要是脂质在真皮内沉积所引起的黄色瘤和脂质在血管内皮沉积所引起的动脉硬化。由于高血脂的发病是一个慢性过程,轻度高血脂通常没有任何不舒服的感觉,较重的会出现头晕目眩,头痛,胸闷,气短,心慌,胸痛,乏力,口角歪斜,不能说话,肢体麻木等症状,最终会导致冠心病,脑中风等严重疾病,并出现相应症状;长期血脂高,脂质在血管内皮沉积所引起的动脉粥样硬化,会引起冠心病和周围动脉疾病等,表现为心绞痛、心肌梗死、脑卒中和间歇性跛行(肢体活动后疼痛)。
目前西医降糖化学药可大致分为口服降糖药物和注射降糖药物,国内常用的口服降糖药物分为促胰岛素分泌剂类、二甲双胍类、α-糖苷酶抑制剂类、噻唑烷二酮衍生物、DDP-4酶抑制剂等;其中促胰岛素分泌剂类又分为磺脲类和非磺脲类(格列奈类)。注射降糖药物有胰岛素及类似药物、GLP-1受体激动剂等。西药降糖药依赖性强,费用高。
中医降糖有许多验方,例如葛根、枸杞子、山萸肉、茯苓、玉竹、桑叶、桑白皮、桑椹、菟丝子、玄参、丹参、知母、仙鹤草、地骨皮、花粉、肉桂等。临床常用黄芪配合滋阴药如生地、玄参、麦冬等治疗糖尿病。
目前西药降脂药主要有两大类,以降低总胆固醇和低密度脂蛋白为主首推他汀类,包括洛伐他汀、辛伐他汀、普伐他汀等,但西药降脂副作用大,一旦漏服更严重。
降血脂中成药有:降脂灵片、通脉降脂片、通泰胶囊、软脉灵、血脂宁胶囊、乌龙降脂茶、玉楂冲剂、健脾降脂冲剂、血脂康等。
检索到中国专利也公开了一些降糖降脂的文献,例如:
CN103041118A中国专利提供一种具有降血糖降血脂作用的组合物,由桑叶或提取物、苦瓜或其提取物、荷叶或其提取物、薤白或提取物组成,利用其中各成分的协同作用,制成口服制剂,如硬胶囊、软胶囊、片剂、颗粒剂、散剂、丸剂、袋泡茶、口服液或液体饮料等。
CN101623495中国专利涉及一种调血脂降血糖的中药组合物,以及该中药组合物制备成口服固体制剂或保健饮料的方法。它所含活性成份的制备原料以重量份计如 下:葛根20-40份、玉米须20-40份、桑叶4-8份、决明子20-40份、山楂 10-20份、生姜4-8份和荷叶5-15份。按配比称取制备原料;将各原料用水煎煮常规方法制备浸膏。
CN102669370A中国专利公开了一种荷叶苦瓜茶及其制备工艺。该荷叶苦瓜茶的原材料包括30-60重量份的苦瓜和40-70重量份的荷叶,它的制备工艺是先取部分荷叶与全部苦瓜经提取浓缩成稠浸膏,再将稠浸膏与经过清洗、干燥、粉碎的剩余荷叶混匀、烘干、分装。
CN103285227A中国专利提供了一种具有降血糖作用、可用于制作保健茶的中药组合物,以及利用该组合物制备的降血糖茶,及其制备方法。该组合物质量配比如下:山楂3~5份,荷叶4~5份,苦瓜10~12份,葛根18~20份,决明子18~20份,肉桂18~20份,甘草3~4份,桑叶1~2份,百合10~12份。
CN105709010A中国专利公开了一种具有辅助降血糖功能的药物组合物,属于中药复方制剂领域。本发明的药物组合物由以下重量份的原料制成:杜仲20~40份、苁蓉15~25份、山药15~25份、积雪草10~20份、罗汉果10~20份、栀子10~20份、荷叶5~15份、枸杞叶5~15份。
CN102578336A中国专利涉及一种桑叶荷叶保健茶及其制备方法,属于保健品技术领域。该方法是将桑叶、荷叶经过筛选清洗、摊晾、蒸气杀青、切片、干燥,再按照其组份按重量份:桑叶1-9份,荷叶1-9份均匀混合包装而成。
CN104107348A中国专利公开了一种降血糖用中草药及其服用方法,每剂中草药包括主药和辅药,其中,主药由黄芪、地骨皮、葛根、黄连、黄芩、番石榴叶、桑白皮、玉米须和玉竹制成,辅药由野菊花、苦瓜、番石榴、枸杞子、五味子、柳叶和银杏叶制成。
CN102204610A中国专利公开了一种银杏保健茶,主要原料有银杏叶、绿茶,其特征在于还有淫羊霍、桑叶。
综上所述,文献和专利公开的资料,基本上是某单个或其中的2-3个添加其他的中药成份,并未明确是以这几种原料作为主要成份,或者在添加多个混合物,但作用已经是被弱化。并且在利用有效成份时,提取的工艺过程不尽相同,在组成混合降糖茶的作用机理不同。
发明内容
本发明的目的是选择多种中国传统的中药原料和茶叶,研制出一种降糖降脂茶,利用荷叶、桑叶、银杏叶、岩茶所含的降血糖降血脂活性成份,提供一套降糖降脂活性物制备工艺,不仅全面地利用了各种降糖降脂活性成份,主剂和辅剂相辅相成,降血糖降血脂作用突出,活性物含量高,并且加工性能稳定。除了具有保健茶的功能外,还具有降糖降脂等优良特性,特别适用于高血糖和高血脂人群。
本发明的技术方案如下:
一种降糖降脂茶,其特征在于由以下原料的重量分数制成:荷叶30-80份、桑叶30-80份、银杏叶20-60份、岩茶40-80份;
所述的岩茶是用夏秋两季采摘的大叶茶叶经过半发酵制备,烘干,粉碎至100目以下,得到岩茶粉末,备用;
所述的荷叶、桑叶是经过采叶、杀青、搓揉、二次杀青、炒制工艺;具体包括:
(1)采叶:分别选取绿色正常的荷叶和桑叶,剪去叶柄,用清水洗净,放竹筐中摊开晾干;
(2)杀青:选干净无异味的大铁锅,加热至250- 300℃锅面呈灰白色,迅速投入荷叶或桑叶,加盖锅闷 1分钟,见锅口有蒸汽时,立即揭盖,用双手迅速从锅底翻抓青叶,均匀抖散至锅底使叶片全部接触锅面,均匀受热,待叶片青草气味消失,呈无光泽的黑绿色,手握成团,略有弹性的出锅;
(3)搓揉:杀青后的叶片,倒在席上晾干带余热用手握成团,揉面团似向同一方面滚揉,反复数次,轻搓宽叶成长条状;
(4)二次杀青:将搓揉后的叶子,放入170-190℃的锅内,双手压在锅内滚炒叶3-5分钟再将叶团展开均匀受热5-10分钟,如此重复约20分钟,出锅摊晾席上回潮变软;
(5)炒成茶:将锅加热至90℃投入晾后的叶子,进行复炒,渐退火降温、轻炒防碎,炒至茶叶烫手时取出,冷却,粉碎粉碎至100目以下,分别得到桑叶和荷叶粉末,备用;
(6)将银杏叶晒干,粉碎至100目以下,得到银杏叶粉末,备用;
(7)将银杏叶粉末以及上述炒成茶的桑叶和荷叶粉末按重量加入2-3倍的水,加入混合酶,进行酶解,时间为4-10小时,温度为35-50℃;
(8)将酶解后的药渣分离;得到酶解液;
(9)药渣加入1倍重量的水,浸泡10-30分钟以后压榨取药液,与酶解液合并,药渣作为饲料添加剂或肥料;
(10)低温真空浓缩,将第(9)步的合并酶解液浓缩为膏状,得到三种植物叶的混合酶解物。
所述的混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶,混合酶中各个组份的重量比为1:1:1:1;
(11)将岩茶粉末与三种植物叶的混合酶解物合并,按重量比例充分混合均匀,制成含片、块状茶剂、袋泡茶或颗粒冲剂。
本发明所述的降糖降脂茶,还包括各组份为:荷叶40份;桑叶80份;银杏叶20份;岩茶80份。
本发明所述的降糖降脂茶,还包括各组份为:荷叶50份;桑叶50份;银杏叶50份;岩茶50份;
本发明所述的降糖降脂茶,还包括各组份为:荷叶80份;桑叶40份;银杏叶40份;岩茶40份。
制备方法与上面相同。
以下是各成分降糖降脂茶的药理情况:
所述的荷叶(Folium Nelumbinis)为多年水生草本植物莲的叶片,其化学成份主要有荷叶碱、柠檬酸、苹果酸、葡萄糖酸、草酸琥珀酸及其它抗有丝分裂作用的碱性成份。药理研究发现,荷叶具有解热、抑菌、解痉作用。经过炮制后的荷叶味苦涩、微咸,性辛凉,具有清暑利湿、升阳发散、祛瘀止血等作用,对多种病症均有一定疗效。荷叶具有以下作用:1.降血压,荷叶碱是荷叶中提取的生物碱,荷叶碱可扩张血管,清热解暑,有降血压的作用;2.防治心血管疾病,荷叶是“药食两用”的食物,荷叶中富含的黄酮类物质,是大多数氧自由基的清除剂,可以提高SOD(超氧化物歧化酶)的活力,减少MDA(脂质过氧化物丙二醛)及0X-LDL(氧化低密度脂蛋白)的生成,它可以增加冠脉流量,对实验性心肌梗塞有对抗作用、对急性心肌缺血有保护作用、对治疗冠心病、高血压等有显著效果、对降低舒张压,防治心律失常、心血管病等也起重要作用;3.减肥,荷叶中的生物碱有降血脂作用,且临床上常用于肥胖症的治疗,荷叶减肥原理,即服用后在人体肠壁上形成一层脂肪隔离膜,有效阻止脂肪的吸收,从根本上减重,并更有效的控制反弹;4.荷叶茶还能明显降低血清中甘油三醇和胆固醇含量,具有调节血脂的保健作用。
所述的桑叶(Mulberry Leaf)为养蚕的植物桑的叶子,含有一种叫做1-脱氧野尻霉素(DNJ)的生物碱,这是一种仅存在于桑叶中的一种生物碱,含量约100mg/100g,这种生物碱是一种α-糖苷酶的抑制剂。桑叶中不仅含有DNJ,而且含有丰富的γ氨基丁酸和醇,其含量是绿茶的3-4倍。桑叶具有减肥、美容、降血糖的作用:1.降血糖,利用桑叶含有一种脱氧霉素,可阻止糖分解酶发挥作用,桑叶原物具有抑制血糖上升的功能,其主要功能成份是桑叶中的“生物碱”,这是一种具有特殊功能的成份,它是其它动、植物所没有的,日本医学界称这种特殊组成为“DNJ”物质,其主要作用是抑制蔗糖酶、麦芽糖酶、a-葡萄糖甘糖、a-淀粉酶的分解,能刺激胰岛素分泌,降低胰岛素分解速度;2.降血压,降血压的主要功效成分是γ-氨基丁酸,桑叶中的γ-氨基丁酸具有降血压的功能,根据动物实验,在自然发生高血压病小白鼠的饲料中加入桑叶粉,经连续喂养数天,发现高血压症状复发次数显著减少,这与桑叶中的γ-氨基丁酸发挥作用有关;3.减肥清脂,桑叶茶可以减肥,就是与桑叶“消肿”、“清血”的作用有关,桑叶茶之所以能够消肿,是因为桑叶有利水的作用,利水作用与利尿作用不同,不光可以促进排尿,还可以使积在细胞中的多余水分排走,所以桑叶茶能够改善所谓的水肿现象,清血是将血液中过剩的中性脂肪和胆固醇排清,血液中的中性脂肪或胆固醇增加过多就是高血脂症,所以胖人多为高脂血症患者,桑叶有改善这种高血脂的作用;4.消疮祛斑更美容,近年来的研究证明,桑叶还有良好的皮肤美容作用,特别是对脸部的痤疮、褐色斑有比较好的疗效,桑叶富含黄酮化合物、酚类、氨基酸、有机酸、胡萝卜素、维生素及多种人体必需的微量元素,这对改善和调节皮肤组织的新陈代谢,特别虽抑制色素沉着的发生和发展均有积极作用,另外,坚持常饮还有减少皮肤或内脏中脂褐质(即老年斑)的积滞;5.高脂血症病人的血液粘度高,在毛细血管中的流动特别不畅通,毛细血管只有我们头发的1/100那么粗,所以容易堵塞,心肌梗塞和脑溢血都是毛细血管堵塞的结果,桑叶中含有强化毛细血管、降低血液粘度的黄酮类成分,所以在减肥、改善高脂血症的同时,又有预防心肌梗塞和脑溢血的作用。
所述的银杏树又名白果树(Ginkgo biloba L.)是我国的瑰宝,珍稀可贵,被誉为地球的“长寿树”、“活化石”。银杏叶中含有天然活性黄酮及苦内酯等与人体健康有益的多种成份,具有溶解胆固醇,扩张血管的作用,对改善脑功能障碍、动脉硬化、高血压、眩晕、耳鸣、头痛、老年痴呆、记忆力减退等有明显效果。经国家卫生部门检测证明:饮用银杏茶可明显降低血清胆固醇、甘油三脂和低密度血脂蛋白,减少体内贮存脂肪的作用,对于高血脂的调节、高血压和冠心病等心脑血管系统疾病患者辅助性防治以及肥胖型人群的减肥等有良好的功效,是目前世界公认的治、防心脑血管疾病最理想的药物成份。植物黄酮类化合物是人体内不可缺少的必要成分,银杏叶同其它中草药配伍,可以更好地发挥其降血压、降血脂、降血液粘稠的作用。植物黄酮类化合物在人体中的作用,主要是增强血管张力、扩张冠状动脉,软化血管、改善血管通透性,降低血压、降低血脂及胆固醇,抗血小板凝集、减少血栓形成,降低血管内的高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG),从而达到降血压、降血脂、降血粘的功效。银杏叶中有重要药理活性作用的成分有两大类:银杏黄酮甙和银杏苦内酯。它们别具一格的作用机制与目前临床上一些常用的心脑血管疾病治疗药物是不相同的:其一是银杏内酯可选择性的抵抗血小板活化因子,血小板活化因子是人体内一种很强的可引发血小板聚集和形成血栓的内源性活性物质,是诱发心脑血管疚病,特别是引起中风、心肌梗死的隐形杀手,危险性很高,而银杏内酯则是血小板活化因子的克星;其二是银杏黄酮甙具有对付自由基的高强本领,银杏黄酮甙已被证实能有效地对抗和消除自由基,并起到延缓衰老的良好作用,特别是近期来自国外的信息,认为银杏叶可用于预防和医治早期老年痴呆症患者,尤对帮助恢复和改善记忆力作用明显;其三是银杏内酯和黄酮甙两者有协同作用,可扩张血管、增加血流量,改善心脑血管循环,在缺氧情况下保护脑和心肌细胞,另外可降低血中甘油三酯,并提高高密度脂蛋白含量,提高红细胞超氧化物歧化酶的活性,故银杏叶提取物的制剂对冠心病、心绞痛、高血脂以及脑震荡、脑外伤后遗症等患者均有较为良好的功效,且一般少见出现不良反应,作为保健药物易为人们接受。本专利所述的银杏叶是经过混合酶提取有效成分制备而成。银杏叶中含有天然活性黄酮及内酯,但银杏叶的有效成分不能泡出来的,医治疗效差。在文献中,提取的方法包括溶剂提取、微波提取、超临界萃取等,经过研究,本发明采用混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶提取,混合酶中各个组份的重量比优选为1:1:1:1。
所述的岩茶产于闽北名山武夷,武夷岩茶具有绿茶之清香,红茶之甘醇,是中国乌龙茶中之极品。武夷岩茶属半发酵茶,制作方法介于绿茶与红茶之间。茶多酚是形成茶叶品质的重要成分之一,是一类存在于茶树中的多羟基酚性化合物的混合物。岩茶主要组分为儿茶素类(黄烷醇类),黄酮、黄酮醇类、花青素类、花白素类和多酚及酚酸类。多酚类在茶鲜叶中含量一般为干物的18~35%。不同品种的茶叶,茶多酚的含量多少亦不等,一般未发酵绿茶和花茶中含量较高,约17~19%,红茶则通常不起过10%。茶多酚所包含的30余种化学物质,绝大多数具有药理作用,这是其它食品与饮料无法相比的,尤其是是它们在冲泡时,能充分地溶解于水,为人体所吸收。大量科学研究包括医学临床试验的结果表明,茶多酚作为一种具有生物活性的天然抗氧化剂,具有以下作用:抑制血管硬化和动脉样硬化,防止内出血,防治高血压和冠心病;抗菌杀菌,治疗痢疾、急性肠胃炎和尿路感染等;使有害金属离子还原成无毒害离子,有解毒之功;活血化瘀,促进纤维蛋白原的溶解,降低血脂,防止血栓形成;抗原子辐射,抗癌变,清除人体细胞自由基。因此,长期饮茶具有良好的抗衰老作用和延年益寿功效。据日本慈惠医科大学中村治雄博士、中国预防医科学院营养与食品卫生研究所实验证实,武夷岩茶有十大功效:1.抗衰老:茶中有茶多酚,提高全血(GSH—PX)的活力,有助于清除体内生物自由基,减少伤害,从而延缓了人体的衰老;2.防癌:茶具有抑制N—甲基—N—硝基—N—亚硝基胍(MNNG)诱发肠道恶性肿瘤的作用,防止癌变;3.提高免疫力:茶可提高CONA刺激脾淋巴细胞增殖反应,保护和调整N—甲基—N—硝基—N—亚硝基胍(MNNG)导致免疫功能,提高体内抗病性;4.防治心血管病:茶可减少主动脉内膜质斑块和含量,降低毛细血管脆性,抗性增强,茶多酚类化合物降低血液中胆固醇、甘油三脂含量,减少脂质沉积,并对血液粘度下降,减少血液高凝状态,防止血栓形成均有明显的影响;5.对牙齿的保健:茶中氟的含量为27.3—146.6 PPM,这种适当含量氟,能防治龋齿,增强骨骼坚韧度;6.防止眼病:茶中胡萝卜素B—紫萝酮是维生素A原,它可转化为维生素A,维生素A能防治上皮组织角质变性增殖泪腺细胞病变,防止角膜角质增厚,防止眼疾;7.其它功效:除上述功能外,尚有止渴、除疾、清凉解毒、兴奋神经中枢、消减疲劳、醒酒、解除酩酊、沉淀有害离子、消炎杀菌、抑制病毒、抗辐射、治辐射内外损伤;8.减肥和美容:由于降低血脂、胆固醇和三酸甘油含量,促进了胰脂肪的分解酶活性,抑制中性脂肪的增加,达到减肥和美容效果;9.保护泌尿器官:茶中含黄酮醇类及苷类化合物,能利尿,抑制肾小管再吸收,促进氟化物排泄,同时还有6,8—二硫辛酸对心脏性水肿、肝脏性水肿和妊娠生水肿都有治疗作用;10.对消化器官的保健:茶中的儿茶素对胃粘膜起收敛作用,适当抑制了胃液的分泌,对胃起着保护作用。
荷叶、桑叶、银杏叶、岩茶是中国传统的中药原料和茶叶,富含降血糖降血脂的有效成份,用传统方法制成了保健茶饮料,推荐给糖尿病人使用,某些已经被申请作为治疗糖尿病药物的专利,长期服用没有副作用。现有科技文献报道的以及已有的专利或产品,主要是基于对荷叶、桑叶、银杏叶、岩茶的降血糖活性成份中对某个提取物的认知,并没有意识到提取物之间化学性质各不相同,以及没有意识到君药和臣药之间的相互作用,所以,其局限性也是明显的。
本发明的有益效果:
1、本发明所提供的降糖降脂茶制备工艺,不仅全面地利用了荷叶、桑叶、银杏叶、岩茶的各种降血糖活性成分,加强了君药和臣药的配合,而且最大限度提高治疗效果,产品加工性能稳定。本发明的降糖茶为按配方比例混匀,适合工业化大生产,均匀性和有效成分都很准确,确保产品质量,使用方便;
2、本发明的降糖降脂茶的原料以桑叶、荷叶为降糖的主要原料,辅以降脂效果优良的岩茶和银杏叶配伍,主辅相配后,辅药可以助主药提高功效,可以起协同作用而增强原有药物的疗效,还可以对人体的心血管等方面都具备了一定的功效,而且没有传统的药物的副作用,研究表明中药制剂在降糖等心血管方面应用的优势,越来越受到国内外的重视;
3、本发明使用的原料荷叶、桑叶来源广泛,具有低廉的原料价格,因此具有良好的经济和社会效益,同时为降糖茶的生产提供了广阔的前景;
4、本发明采用科学的焙烤工艺和方法除去了荷叶、桑叶中有机酸的苦味、涩味,口味甘醇,清香溢人。用开水冲泡,清澈明亮,清香甘甜,鲜醇爽口,尤其对中老年人及不宜饮茶的人提供了一种新型饮品,达到更好的保健效果,有利于养生保健,延年益寿。
5、本发明的银杏叶的有效成份是经过混合酶提取有效成分制备而成,混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶,混合酶中各个组份的重量比为1:1:1:1。经过酶的提取,银杏总黄酮的提取率比普通的醇提法提高了20%-30%,而且,生物酶法除了提取效率高,还具备了无污染、不易造成有限资源的浪费的有益效果。
6、本发明的降糖降脂茶具有安全稳定,无毒无副作用,适合中老年糖尿病患者的使用;心脑血管病人群的辅助治疗,更具正常人群的养生保健功能。
具体实施方式
实施例1:
一种降糖降脂茶,各组份优选为:荷叶40份、桑叶80份、银杏叶20份、岩茶80份。具体步骤如下:
1、荷叶、桑叶经过采叶、杀青、搓揉、二次杀青、炒制等烘焙工艺,再经过超微粉碎成粉末。a.采叶:绿色正常叶片,放筐中用清水洗净,摊开晾干,随采随炒,以保质量。b.杀青:选干净无异味的大铁锅,加热至250- 300℃锅面呈灰白色,迅速投入青叶盖锅盖闷 1分钟,见锅口有蒸汽时,立即揭盖,用双手迅速从锅底翻抓青叶,均匀抖散至锅底使叶片全部接触锅面,均匀受热,待叶片青草气味消失,呈无光泽的黑绿色,手握成团,略有弹性的出锅。c.搓揉:杀青后的叶片,倒在席上晾干带余热用手握成团,揉面团似向同一方面滚揉,反复数次,轻搓宽叶成长条状。d.二次杀青:将搓揉后的叶子,放入170-190℃的锅内,双手压在锅内滚炒叶数分钟再将叶团展开均匀受热几分钟,如此重复约20分钟,出锅摊晾席上回潮变软。e.炒成茶:将锅加热至90℃投入晾后的叶子,进行复炒,渐退火降温、轻炒防碎,炒至茶叶烫手时取出,冷却。f.超微粉碎:将荷叶、桑叶粉碎至D90<10μm;
2、将银杏叶晒干,粉碎至100目以下,得到银杏叶粉末,备用;
3、将银杏叶粉末以及上述炒成茶的桑叶和荷叶粉末按重量加入2-3倍的水,加入混合酶,进行酶解,时间为4-10小时,温度为35-50℃;
4、将酶解后的药渣分离;得到酶解液;
5、药渣加入1倍重量的水,浸泡10-30分钟以后压榨取药液,与酶解液合并,药渣作为饲料添加剂或肥料;
6、低温真空浓缩,将第5步的合并酶解液浓缩为膏状,得到三种植物叶的混合酶解物。
所述的混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶,混合酶中各个组份的重量比为1:1:1:1;
7、将岩茶粉末与三种植物叶的混合酶解物合并,按重量比例充分混合均匀,将物料按照配方混合均匀,用袋泡茶包装机进行袋泡茶包装,完成内袋滤纸送入、折袋、封边、进茶、封口和送线、折粘标签等工序,即得到降糖降脂茶袋泡茶产品。
实施例2:
一种降糖降脂茶,各组份优选为:荷叶50份、桑叶50份、银杏叶50份、岩茶70份。具体步骤如下:
1、荷叶、桑叶经过采叶、杀青、搓揉、二次杀青、炒制等烘焙工艺,再经过超微粉碎成粉末。a.采叶:绿色正常叶片,放筐中用清水洗净,摊开晾干,随采随炒,以保质量。b.杀青:选干净无异味的大铁锅,加热至250- 300℃锅面呈灰白色,迅速投入青叶盖锅盖闷 1分钟,见锅口有蒸汽时,立即揭盖,用双手迅速从锅底翻抓青叶,均匀抖散至锅底使叶片全部接触锅面,均匀受热,待叶片青草气味消失,呈无光泽的黑绿色,手握成团,略有弹性的出锅。c.搓揉:杀青后的叶片,倒在席上晾干带余热用手握成团,揉面团似向同一方面滚揉,反复数次,轻搓宽叶成长条状。d.二次杀青:将搓揉后的叶子,放入170-190℃的锅内,双手压在锅内滚炒叶数分钟再将叶团展开均匀受热几分钟,如此重复约20分钟,出锅摊晾席上回潮变软。e.炒成茶:将锅加热至90℃投入晾后的叶子,进行复炒,渐退火降温、轻炒防碎,炒至茶叶烫手时取出,冷却。f.超微粉碎:将荷叶、桑叶粉碎至D90<10μm;
2、将银杏叶晒干,粉碎至100目以下,得到银杏叶粉末,备用;
3、将银杏叶粉末以及上述炒成茶的桑叶和荷叶粉末按重量加入2-3倍的水,加入混合酶,进行酶解,时间为4-10小时,温度为35-50℃;
4、将酶解后的药渣分离;得到酶解液;
5、药渣加入1倍重量的水,浸泡10-30分钟以后压榨取药液,与酶解液合并,药渣作为饲料添加剂或肥料;
6、低温真空浓缩,将第5步的合并酶解液浓缩为膏状,得到三种植物叶的混合酶解物。
所述的混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶,混合酶中各个组份的重量比为1:1:1:1;
7、将岩茶粉末与三种植物叶的混合酶解物合并,按重量比例充分混合均匀,加入麦芽糊精赋形剂,将所有物料按照配比投入混合机中混合,调整物料湿度,投入摇摆式颗粒机进行造粒,过14目筛,制得湿颗粒;
8、湿颗粒置于沸腾干燥机中干燥,水分含量降至3%左右,包装机包装即得袋装颗粒剂降糖降脂茶。
实施例3:
一种降糖降脂茶,各组份优选为:荷叶65份、桑叶45份、银杏叶45份、岩茶40份。具体步骤如下:
1、荷叶、桑叶经过采叶、杀青、搓揉、二次杀青、炒制等烘焙工艺,再经过超微粉碎成粉末。a.采叶:绿色正常叶片,放筐中用清水洗净,摊开晾干,随采随炒,以保质量。b.杀青:选干净无异味的大铁锅,加热至250- 300℃锅面呈灰白色,迅速投入青叶盖锅盖闷 1分钟,见锅口有蒸汽时,立即揭盖,用双手迅速从锅底翻抓青叶,均匀抖散至锅底使叶片全部接触锅面,均匀受热,待叶片青草气味消失,呈无光泽的黑绿色,手握成团,略有弹性的出锅。c.搓揉:杀青后的叶片,倒在席上晾干带余热用手握成团,揉面团似向同一方面滚揉,反复数次,轻搓宽叶成长条状。d.二次杀青:将搓揉后的叶子,放入170-190℃的锅内,双手压在锅内滚炒叶数分钟再将叶团展开均匀受热几分钟,如此重复约20分钟,出锅摊晾席上回潮变软。e.炒成茶:将锅加热至90℃投入晾后的叶子,进行复炒,渐退火降温、轻炒防碎,炒至茶叶烫手时取出,冷却。f.超微粉碎:将荷叶、桑叶粉碎至D90<10μm;
2、将银杏叶晒干,粉碎至100目以下,得到银杏叶粉末,备用;
3、将银杏叶粉末以及上述炒成茶的桑叶和荷叶粉末按重量加入2-3倍的水,加入混合酶,进行酶解,时间为4-10小时,温度为35-50℃;
4、将酶解后的药渣分离;得到酶解液;
5、药渣加入1倍重量的水,浸泡10-30分钟以后压榨取药液,与酶解液合并,药渣作为饲料添加剂或肥料;
6、低温真空浓缩,将第5步的合并酶解液浓缩为膏状,得到三种植物叶的混合酶解物。
所述的混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶,混合酶中各个组份的重量比为1:1:1:1;
7、将岩茶粉末与三种植物叶的混合酶解物合并,按重量比例充分混合均匀,加入柠檬酸0.8%、β―环状糊精1.1%、阿巴斯甜适量,还有硬脂酸镁和滑石粉;将各物料混合均匀,调节物料水分,经过颗粒机制备颗粒,烘干,用压片机压制成型,即得到降糖降脂茶含片产品。
实施例4:
一种降糖降脂茶含片,各组份优选为:荷叶75份、桑叶32份、银杏叶68份、岩茶45份。具体步骤如下:
1、荷叶、桑叶经过采叶、杀青、搓揉、二次杀青、炒制等烘焙工艺,再经过超微粉碎成粉末。a.采叶:绿色正常叶片,放筐中用清水洗净,摊开晾干,随采随炒,以保质量。b.杀青:选干净无异味的大铁锅,加热至250- 300℃锅面呈灰白色,迅速投入青叶盖锅盖闷 1分钟,见锅口有蒸汽时,立即揭盖,用双手迅速从锅底翻抓青叶,均匀抖散至锅底使叶片全部接触锅面,均匀受热,待叶片青草气味消失,呈无光泽的黑绿色,手握成团,略有弹性的出锅。c.搓揉:杀青后的叶片,倒在席上晾干带余热用手握成团,揉面团似向同一方面滚揉,反复数次,轻搓宽叶成长条状。d.二次杀青:将搓揉后的叶子,放入170-190℃的锅内,双手压在锅内滚炒叶数分钟再将叶团展开均匀受热几分钟,如此重复约20分钟,出锅摊晾席上回潮变软。e.炒成茶:将锅加热至90℃投入晾后的叶子,进行复炒,渐退火降温、轻炒防碎,炒至茶叶烫手时取出,冷却。F.超微粉碎:将荷叶、桑叶粉碎至D90<10μm;
2、将银杏叶晒干,粉碎至100目以下,得到银杏叶粉末,备用;
3、将银杏叶粉末以及上述炒成茶的桑叶和荷叶粉末按重量加入2-3倍的水,加入混合酶,进行酶解,时间为4-10小时,温度为35-50℃;
4、将酶解后的药渣分离;得到酶解液;
5、药渣加入1倍重量的水,浸泡10-30分钟以后压榨取药液,与酶解液合并,药渣作为饲料添加剂或肥料;
6、低温真空浓缩,将第5步的合并酶解液浓缩为膏状,得到三种植物叶的混合酶解物。
所述的混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶,混合酶中各个组份的重量比为1:1:1:1;
7、将岩茶粉末与三种植物叶的混合酶解物合并,按重量比例充分混合均匀,将物料按照配方混合均匀,用袋泡茶包装机进行袋泡茶包装,完成内袋滤纸送入、折袋、封边、进茶、封口和送线、折粘标签等工序,即得到降糖降脂茶袋泡茶产品。
实施例5:
一种降糖降脂茶,各组份优选为:荷叶38份、桑叶65份、银杏叶34份、岩茶70份。具体步骤如下:
1、荷叶、桑叶经过采叶、杀青、搓揉、二次杀青、炒制等烘焙工艺,再经过超微粉碎成粉末。a.采叶:绿色正常叶片,放筐中用清水洗净,摊开晾干,随采随炒,以保质量。b.杀青:选干净无异味的大铁锅,加热至250- 300℃锅面呈灰白色,迅速投入青叶盖锅盖闷 1分钟,见锅口有蒸汽时,立即揭盖,用双手迅速从锅底翻抓青叶,均匀抖散至锅底使叶片全部接触锅面,均匀受热,待叶片青草气味消失,呈无光泽的黑绿色,手握成团,略有弹性的出锅。c.搓揉:杀青后的叶片,倒在席上晾干带余热用手握成团,揉面团似向同一方面滚揉,反复数次,轻搓宽叶成长条状。d.二次杀青:将搓揉后的叶子,放入170-190℃的锅内,双手压在锅内滚炒叶数分钟再将叶团展开均匀受热几分钟,如此重复约20分钟,出锅摊晾席上回潮变软。e.炒成茶:将锅加热至90℃投入晾后的叶子,进行复炒,渐退火降温、轻炒防碎,炒至茶叶烫手时取出,冷却。F.超微粉碎:将荷叶、桑叶粉碎至D90<10μm;
2、将银杏叶晒干,粉碎至100目以下,得到银杏叶粉末,备用;
3、将银杏叶粉末以及上述炒成茶的桑叶和荷叶粉末按重量加入2-3倍的水,加入混合酶,进行酶解,时间为4-10小时,温度为35-50℃;
4、将酶解后的药渣分离,得到酶解液;
5、药渣加入1倍重量的水,浸泡10-30分钟以后压榨取药液,与酶解液合并,药渣作为饲料添加剂或肥料;
6、低温真空浓缩,将第5步的合并酶解液浓缩为膏状,得到三种植物叶的混合酶解物。
所述的混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶,混合酶中各个组份的重量比为1:1:1:1;
7、将岩茶粉末与三种植物叶的混合酶解物合并,按重量比例充分混合均匀,加入麦芽糊精赋形剂,将所有物料按照配比投入混合机中混合,调整物料湿度,投入摇摆式颗粒机进行造粒,过14目筛网,
8、湿颗粒置于沸腾干燥机中干燥,水分含量降至3%左右,包装机包装即得袋装颗粒剂降糖降脂茶产品。
实施例6:
一种降糖降脂茶,各组份优选为:荷叶66份、桑叶43份、银杏叶58份、岩茶48份。具体步骤如下:
1、荷叶、桑叶经过采叶、杀青、搓揉、二次杀青、炒制等烘焙工艺,再经过超微粉碎成粉末。a.采叶:绿色正常叶片,放筐中用清水洗净,摊开晾干,随采随炒,以保质量。b.杀青:选干净无异味的大铁锅,加热至250- 300℃锅面呈灰白色,迅速投入青叶盖锅盖闷 1分钟,见锅口有蒸汽时,立即揭盖,用双手迅速从锅底翻抓青叶,均匀抖散至锅底使叶片全部接触锅面,均匀受热,待叶片青草气味消失,呈无光泽的黑绿色,手握成团,略有弹性的出锅。c.搓揉:杀青后的叶片,倒在席上晾干带余热用手握成团,揉面团似向同一方面滚揉,反复数次,轻搓宽叶成长条状。d.二次杀青:将搓揉后的叶子,放入170-190℃的锅内,双手压在锅内滚炒叶数分钟再将叶团展开均匀受热几分钟,如此重复约20分钟,出锅摊晾席上回潮变软。e.炒成茶:将锅加热至90℃投入晾后的叶子,进行复炒,渐退火降温、轻炒防碎,炒至茶叶烫手时取出,冷却。F.超微粉碎:将荷叶、桑叶粉碎至D90<10μm;
2、将银杏叶晒干,粉碎至100目以下,得到银杏叶粉末,备用;
3、将银杏叶粉末以及上述炒成茶的桑叶和荷叶粉末按重量加入2-3倍的水,加入混合酶,进行酶解,时间为4-10小时,温度为35-50℃;
4、将酶解后的药渣分离,得到酶解液;
5、药渣加入1倍重量的水,浸泡10-30分钟以后压榨取药液,与酶解液合并,药渣作为饲料添加剂或肥料;
6、低温真空浓缩,将第5步的合并酶解液浓缩为膏状,得到三种植物叶的混合酶解物。
所述的混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶,混合酶中各个组份的重量比为1:1:1:1;
7、将岩茶粉末与三种植物叶的混合酶解物合并,按重量比例充分混合均匀,加入柠檬酸0.8%、β―环状糊精1.1%、阿巴斯甜适量,还有硬脂酸镁和滑石粉;将各物料混合均匀,调节物料水分,经过颗粒机制备颗粒,烘干,用压片机压片成型,即得到降糖降脂茶含片产品。
应用实施例
2014-2016年给高血糖的志愿者试用本发明实施例1-6的降糖降脂茶,服用2个月,效果如下:
试用人数 | 降血糖效果 | 降血脂效果 | |
实施例1 | 20 | 20(总)/18(有效) | 20(总)/16(有效) |
实施例2 | 25 | 25(总)/21(有效) | 25(总)/16(有效) |
实施例3 | 22 | 22(总)/19(有效) | 22(总)/18(有效) |
实施例4 | 23 | 23(总)/15(有效) | 23(总)/16(有效) |
实施例5 | 30 | 30(总)/22(有效) | 30(总)/20(有效) |
实施例6 | 28 | 28(总)/25(有效) | 28(总)/17(有效) |
注:1、显示的效果是志愿者经正规医院进行血糖、血脂的检测,
2、试验者饮食习惯不改变,原服用西药的也不变。
具体病例:
1、刘**,男,53岁,患高血压和高血脂,医院检查FBG:9.1mM,2hBG:15.4mM;血脂:谷丙转氨酶44U/L,甘油三脂6.55mmol/L,胆固醇6.22mmol/L,低密度脂蛋白3.72mmol/L。常期服用西药,经过降糖茶配合治疗二个月后,医院检查FBG控制在5.8-7.3mM。血糖水平平稳下降,血脂复查未见异常。
2、覃**,女,41岁,患高血压和高血脂,糖尿病史4年,空腹血糖水平为8.5mmol/L,2hBG:13.2mM;血脂:谷丙转氨酶44U/L,甘油三脂6.55mmol/L,胆固醇6.22mmol/L,低密度脂蛋白3.72mmol/L。经过降糖茶配合治疗二个月后,医院检查FBG:5.8mM。血脂复查未见异常。
3、张**,女,69岁,患慢性糖尿病5年,并发患有高血压、视力模糊。医院检测医院检查FBG:10.3mM,2hBG:14.5mM;血脂:甘油三脂3.15mmol/L,胆固醇5.81mmol/L,低密度脂蛋白4.05mmol/L。经过降糖茶配合治疗二个月后,血糖水平仍保持正常,并使血压得到控制,医院检查FBG:6.9mM。血脂复查未见异常。
4、陈**,女,55岁,慢性糖尿病,服用多种降糖药物效果不佳,患者视力模糊,腿疼无力,手脚麻木。医院检测医院检查FBG:8.9mM,2hBG:13.8mM;血脂:谷丙转氨酶41U/L,甘油三脂2.9mmol/L,胆固醇5.52mmol/L,低密度脂蛋白3.34mmol/L。经过降糖茶配合治疗二个月后,血糖明显下降,医院检查FBG控制在6.3mM。血脂复查未见异常。
Claims (4)
1.一种降糖降脂茶,其特征在于:由以下原料的重量分数制成:荷叶30-80份、桑叶30-80份、银杏叶20-60份、岩茶40-80份;
所述的岩茶是用夏秋两季采摘的大叶茶叶经过半发酵制备,烘干,粉碎至100目以下,得到岩茶粉末,备用;
所述的荷叶、桑叶是经过采叶、杀青、搓揉、二次杀青、炒制工艺;具体包括:
(1)采叶:分别选取绿色正常的荷叶和桑叶,剪去叶柄,用清水洗净,放竹筐中摊开晾干;
(2)杀青:选干净无异味的大铁锅,加热至250- 300℃锅面呈灰白色,迅速投入荷叶或桑叶,加盖锅闷 1分钟,见锅口有蒸汽时,立即揭盖,用双手迅速从锅底翻抓青叶,均匀抖散至锅底使叶片全部接触锅面,均匀受热,待叶片青草气味消失,呈无光泽的黑绿色,手握成团,略有弹性的出锅;
(3)搓揉:杀青后的叶片,倒在席上晾干带余热用手握成团,揉面团似向同一方面滚揉,反复数次,轻搓宽叶成长条状;
(4)二次杀青:将搓揉后的叶子,放入170-190℃的锅内,双手压在锅内滚炒叶3-5分钟再将叶团展开均匀受热5-10分钟,如此重复约20分钟,出锅摊晾席上回潮变软;
(5)炒成茶:将锅加热至90℃投入晾后的叶子,进行复炒,渐退火降温、轻炒防碎,炒至茶叶烫手时取出,冷却,粉碎粉碎至100目以下,分别得到桑叶和荷叶粉末,备用;
(6)将银杏叶晒干,粉碎至100目以下,得到银杏叶粉末,备用;
(7)将银杏叶粉末以及上述炒成茶的桑叶和荷叶粉末按重量加入2-3倍的水,加入混合酶,进行酶解,时间为4-10小时,温度为35-50℃;
(8)将酶解后的药渣分离;得到酶解液;
(9)药渣加入1倍重量的水,浸泡10-30分钟以后压榨取药液,与酶解液合并,药渣作为饲料添加剂或肥料;
(10)低温真空浓缩,将第(9)步的合并酶解液浓缩为膏状,得到三种植物叶的混合酶解物;
所述的混合酶包括纤维素酶、木糖醇酶、果胶酶、β﹣葡聚糖酶,混合酶中各个组份的重量比为1:1:1:1;
(11)将岩茶粉末与三种植物叶的混合酶解物合并,按重量比例充分混合均匀,制成含片、块状茶剂、袋泡茶或颗粒剂。
2.根据权利要求1所述的降糖降脂茶,其特征在于包括各组份为:荷叶40份;桑叶80份;银杏叶20份;岩茶80份。
3.根据权利要求1所述的降糖降脂茶,其特征在于包括各组份为:荷叶50份;桑叶50份;银杏叶50份;岩茶50份。
4.根据权利要求1所述的降糖降脂茶,其特征在于包括各组份为:荷叶80份;桑叶40份;银杏叶40份;岩茶40份。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710739433.2A CN107494817A (zh) | 2017-08-25 | 2017-08-25 | 一种降糖降脂茶 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710739433.2A CN107494817A (zh) | 2017-08-25 | 2017-08-25 | 一种降糖降脂茶 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107494817A true CN107494817A (zh) | 2017-12-22 |
Family
ID=60693019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710739433.2A Pending CN107494817A (zh) | 2017-08-25 | 2017-08-25 | 一种降糖降脂茶 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107494817A (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110973311A (zh) * | 2019-12-20 | 2020-04-10 | 唐昌 | 一种降糖茶及其制备方法 |
CN113796537A (zh) * | 2021-09-22 | 2021-12-17 | 尚品生物科技(天津)有限公司 | 一种降糖组合物及其制作工艺 |
CN114403445A (zh) * | 2022-01-26 | 2022-04-29 | 四川默森药业有限公司 | 一种桑叶黄酮的提取及其在功能性食品中的应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102972544A (zh) * | 2011-09-07 | 2013-03-20 | 董根荣 | 一种降脂降压保健茶及其制备方法 |
CN103652104A (zh) * | 2012-09-03 | 2014-03-26 | 孙儒 | 一种银杏茶的手工制作方法 |
CN104906153A (zh) * | 2015-06-09 | 2015-09-16 | 邳州鑫源生物制品有限公司 | 一种高效提取银杏黄酮的工艺方法 |
CN106578218A (zh) * | 2016-12-02 | 2017-04-26 | 广西中港高科国宝金花茶产业有限公司 | 酸性小分子团水提取金花茶有效成分的方法及用途 |
CN106581091A (zh) * | 2016-11-25 | 2017-04-26 | 黄能 | 赤苍藤的提取方法及作为治疗痛风药物的用途 |
CN106668294A (zh) * | 2017-01-04 | 2017-05-17 | 南京中医药大学 | 具有降血糖、降血脂和降血压功效的丹参叶复合保健茶及其制备方法和用途 |
-
2017
- 2017-08-25 CN CN201710739433.2A patent/CN107494817A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102972544A (zh) * | 2011-09-07 | 2013-03-20 | 董根荣 | 一种降脂降压保健茶及其制备方法 |
CN103652104A (zh) * | 2012-09-03 | 2014-03-26 | 孙儒 | 一种银杏茶的手工制作方法 |
CN104906153A (zh) * | 2015-06-09 | 2015-09-16 | 邳州鑫源生物制品有限公司 | 一种高效提取银杏黄酮的工艺方法 |
CN106581091A (zh) * | 2016-11-25 | 2017-04-26 | 黄能 | 赤苍藤的提取方法及作为治疗痛风药物的用途 |
CN106578218A (zh) * | 2016-12-02 | 2017-04-26 | 广西中港高科国宝金花茶产业有限公司 | 酸性小分子团水提取金花茶有效成分的方法及用途 |
CN106668294A (zh) * | 2017-01-04 | 2017-05-17 | 南京中医药大学 | 具有降血糖、降血脂和降血压功效的丹参叶复合保健茶及其制备方法和用途 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110973311A (zh) * | 2019-12-20 | 2020-04-10 | 唐昌 | 一种降糖茶及其制备方法 |
CN113796537A (zh) * | 2021-09-22 | 2021-12-17 | 尚品生物科技(天津)有限公司 | 一种降糖组合物及其制作工艺 |
CN113796537B (zh) * | 2021-09-22 | 2023-08-22 | 尚品生物科技(天津)有限公司 | 一种降糖组合物及其制作工艺 |
CN114403445A (zh) * | 2022-01-26 | 2022-04-29 | 四川默森药业有限公司 | 一种桑叶黄酮的提取及其在功能性食品中的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107296949A (zh) | 药食同源复合制剂及其制备方法和应用 | |
CN101011561B (zh) | 黄连温胆汤现代中药口服制剂及其生产方法 | |
CN102872306B (zh) | 治疗心脑血管疾病的复方富硒中药组合物及其制备方法 | |
CN103041118B (zh) | 一种具有降血糖降血脂作用的组合物 | |
CN101502627A (zh) | 防治酒精性肝病的中药保健品制剂及其制备方法 | |
CN104904964A (zh) | 一种降糖降脂的罗布麻叶保健茶及其制备方法 | |
CN103127232A (zh) | 桑叶方总提物及其制剂和用途 | |
CN104351411A (zh) | 一种青钱柳叶复合消渴保健含片及其制备方法 | |
CN106819297A (zh) | 一种参杞花果茶及其制备方法 | |
CN107494817A (zh) | 一种降糖降脂茶 | |
CN104666643B (zh) | 一种复方雪菊产品及其制备方法和应用 | |
CN101658641A (zh) | 含天麻杜仲叶苦丁茶的保健制剂及其制备方法 | |
CN106668294A (zh) | 具有降血糖、降血脂和降血压功效的丹参叶复合保健茶及其制备方法和用途 | |
KR100923043B1 (ko) | 한방생약 혈압치료제 및 그 제조방법 | |
CN105341944A (zh) | 一种提高免疫力的丹参口服液及其制备方法 | |
JP2004352626A (ja) | 植物由来成分を含有する抗コレステロール剤 | |
KR20040081248A (ko) | 울금추출물이 함유된 기능성 한방입욕제의 제조방법 | |
CN104606571A (zh) | 一种生津止渴鲜菠菜根代茶饮及制备方法 | |
CN103919229A (zh) | 一种安眠定神保健速溶粉及其制备方法 | |
CN107788180A (zh) | 一种稳定降血压的保健养生茶及其制备方法 | |
KR101652507B1 (ko) | 눈 건강개선 한약 조성물 및 이를 이용한 한약 제제 | |
CN108379500A (zh) | 一种养肝解酒醒酒防口臭的麦苗中药组合物及制备方法 | |
US11628196B1 (en) | Method for preparing health foods comprising aloeswood having effects of preventing absorption of heavy metals into body and excreting the same from body | |
CN106819252A (zh) | 降血脂养颜美容茶及其制备方法 | |
CN106615362A (zh) | 一种糖尿病人专用保健茶及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171222 |
|
RJ01 | Rejection of invention patent application after publication |